Oncology Micro learning

PARP inhibitors in prostate cancer and the rationale behind combination treatment – Module 2

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Assoc. Prof. Alicia Morgans

Dr Pasquale Rescigno

Publication Date

Jan 2023

I agree that this educational programme:

Was valuable to me

1/4

Has improved my knowledge of this topic:

2/4

Is likely to change my clinical practice:

3/4

Was balanced and unbiased:

4/4

In this micro learning programme, you'll learn about PARP inhibitors in prostate cancer from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno.

Learning resources include videos, slides, flashcards and assessments. Complete both modules to earn your CME credit.

What you'll learn

Module 1 covers the use of PARP inhibitors as monotherapy in advanced prostate cancer
Module 2 explains the rationale behind combination treatment with anti-androgens

Clinical takeaways:

PARP inhibitors are effective drugs as monotherapy in mCRPC patients with HRR alterations
Genetic testing is important to help with treatment decision-making and for understanding inherited risk
BRCA mutations are associated with poor outcomes in mCRPC patients
Patients with tumours harbouring BRCA1/BRCA2 alterations appear to derive the greatest clinical benefit from PARPi, but patients with other HRR alterations also derive benefit
PARP inhibitors combined with novel hormonal agents are effective as a first-line treatment option for mCRPC patients with an HRR mutation. Certain combinations, such as olaparib plus abiraterone, have also shown benefits in patients regardless of their HRR status

This PARP Inhibitors in Prostate Cancer micro e-learning programme is endorsed by

Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Assoc. Prof. Alicia Morgans has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix.

Dr Pasquale Rescigno is Clinical Senior Lecturer at the Translational and Clinical Research Institute at Newcastle University, UK. He is the former Head of the Translational and Clinical Trial Team on GU Cancers at the Istituto di Candiolo FPO-IRCCS (Candiolo Cancer Institute), Clinical Research Fellow at the Institute of Cancer Research (London), and Prostate Cancer Foundation Young Investigator awardee.

His research mainly focuses on the study of mechanisms/pathways that are disrupted in prostate cancer (such as PTEN/PI3K/AKT, TP53 and RB1), and on the identification and validation of predictive, prognostic and efficacy-response biomarkers for novel agents targeting the PI3K/AKT, DNA repair systems and the PD-1/PDL-1 pathways.

He has served as Principal and Sub-investigator of several phase I/II/III Clinical Trials and designed and is the Clinical Coordinator and Principal Investigator of UK and Italian national research projects (MAESTRO, an umbrella trial and PERSEUS1 in the UK; BITCOIN and BRIDGE in Italy).

More recently, his research activity focused on the study of gut microbiome in prostate cancer.